Dabrafenib in BRAF V600E–Mutant Advanced Non-Small Cell Lung Cancer: an Open-label, Single arm, Multicenter, Phase 2 Trial

BACKGROUND: Activating BRAF V600E mutations are found in approximately 1–2% of adenocarcinomas of the lung offering an opportunity to test targeted therapy for this disease. Dabrafenib is an oral selective inhibitor of the BRAF kinase. The aim of this study was to assess the clinical activity of dab...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet Oncol
Main Authors: Planchard, David, Kim, Tae Min, Mazieres, Julien, Quoix, Elisabeth, Riely, Gregory, Barlesi, Fabrice, Souquet, Pierre-John, Smit, Egbert F., Groen, Harry J. M., Kelly, Ronan J., Cho, B. C., Socinski, Mark A., Pandite, Lini, Nase, Christine, Ma, Bo, D’Amelio, Anthony, Mookerjee, Bijoyesh, Curtis, C. Martin, Johnson, Bruce E.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5006181/
https://ncbi.nlm.nih.gov/pubmed/27080216
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(16)00077-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados